Organisation: Amgen

mRNA firms and other biopharma patentees dominate ‘Innovation Momentum’ rankings

Newly released report throws light on which life sciences companies have the most dynamic IP portfolios

22 February 2024

Alexion injunction against Amgen overturned in landmark Munich appeal

Reversal has major implications for future disputes involving rare disease treatments

12 February 2024

Specialist Chapter: Trends and Strategies in Global Pharma and Biotech Patent Litigation

Featured in The Patent Litigation Review 2024

International patent protection is now part-and-parcel for any significant drug or therapeutic, and, as a result, disputes over patent ownership and infringement now regularly implicate a myriad of related laws across international venues. In recent years, there has been a trend towards more complex and high-stakes global patent disputes in the pharmaceutical industry, including parallel litigation across multiple jurisdictions.

29 January 2024

Specialist Chapter: First Months of UPC See Broad Sector Engagement and CMS Teething Problems

Featured in The Patent Litigation Review 2024

The number of UPC actions filed in the first three months indicates that many rights holders are willing to engage with the new system, especially in Germany. As the court becomes more settled, the next 12 months could prove transformative for European patent litigation.

24 November 2023

Biosimilars and biologics litigation in the United States

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Whether the new Inflation Reduction Act will protect and foster the growing biosimilar market remains to be seen, but litigation in the biosimilars space has already transformed the landscape, making it increasingly difficult to navigate for biopharma companies and IP professionals.

25 August 2023

Five things to watch in US Supreme Court oral argument in Amgen v Sanofi

Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112

15 March 2023

Unlock unlimited access to all IAM content